Drugs / ChAd155-hIi-HBV
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03866187 | Mar 2019 → Oct 2024 | chronic hepatitis B virus infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05276297 | Mar 2022 → Aug 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAd155-hIi-HBV | “1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.” NCT05276297 ↗ |
| Known as | Chimpanzee adenovirus HBV vaccine | “one dose of Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation on Day 1” NCT03866187 ↗ |
| Modality | Vaccine | “Chimpanzee adenovectored HBV vaccine” NCT05276297 ↗ |
| Route | Intramuscular | “by intramuscular injection in the deltoid of the non-dominant arm” NCT03866187 ↗ |